Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

CLTI

  • Home
  • CLTI
Drug-Eluting Resorbable Scaffold Maintains a 3-Year Patency Advantage Over Angioplasty in Infrapopliteal CLTI
Posted inCardiology General Surgery news

Drug-Eluting Resorbable Scaffold Maintains a 3-Year Patency Advantage Over Angioplasty in Infrapopliteal CLTI

Posted by MedXY By MedXY 05/15/2026
Three-year LIFE-BTK data show sustained patency and reintervention benefits with a drug-eluting resorbable scaffold versus angioplasty in selected patients with infrapopliteal CLTI, with comparable limb salvage and safety.
Read More
Intramuscular Adipose Tissue Accumulation as a Key Determinant of Muscle Dysfunction in Peripheral Artery Disease
Posted inCardiology Clinical Updates news

Intramuscular Adipose Tissue Accumulation as a Key Determinant of Muscle Dysfunction in Peripheral Artery Disease

Posted by MedXY By MedXY 03/10/2026
This review synthesizes evidence that intramuscular adipose tissue (IMAT) accumulation, driven by fibroadipogenic progenitors, is a primary driver of limb dysfunction in PAD/CLTI, identifying IMAT as a novel therapeutic target.
Read More
  • Optimizing Needle Thoracostomy in Obese Patients: Chest Wall Thickness Influences on Site Selection and Needle Length
  • SSRIs vs. Second-Generation Antipsychotics for Managing Agitation in Dementia: Real-World Evidence from Nursing Homes
  • Initiation, Adherence, and Persistence to Guideline-Directed Medical Therapy After Heart Failure Hospitalization: Bridging the Gap Between Prescription and Sustained Use
  • Olorofim for Poorly Controlled Disseminated Coccidioidomycosis: Phase 2b Clinical Efficacy and Safety Insights
  • Bridging Periodontitis and Clonal Hematopoiesis: Implications for Solid Tumor Metastasis, Clinical Trial Design, and Microbiome Dynamics
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in